ACM
CGON icon

Aster Capital Management’s CG Oncology CGON Stock Holding History

Aster Capital Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-192
Closed -$4.96K – 1107
2025
Q1 		$4.96K Buy
+192
New +$5.4K ﹤0.01% 1121

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aster Capital Management's CGON Position: Q2 2025 in Review

Aster Capital Management sold out of CG Oncology (CGON) in Q2 2025, closing a stake of 192 shares — an estimated $4.96K sold.

Aster Capital Management first reported a position in CGON in Q1 2025 and held it in 1 quarter. The position peaked at $4.96K in Q1 2025. 162 funds tracked by Wall St. Rank hold CGON as of Q2 2025.

  • Aster Capital Management reported no remaining CG Oncology position as of Q2 2025 after selling out during the quarter.
  • Aster Capital Management sold 192 CG Oncology shares in Q2 2025, an estimated $4.96K.
  • Aster Capital Management first reported a position in CG Oncology in Q1 2025 and held it in 1 quarter.
  • Aster Capital Management's CG Oncology position peaked at $4.96K in Q1 2025.
  • 162 funds tracked by Wall St. Rank held CG Oncology as of Q2 2025.

Based on Aster Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.